KemPharm Inc (KMPH) : Arete Wealth Advisors scooped up 57,233 additional shares in KemPharm Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 13, 2016. The investment management firm now holds a total of 1,044,344 shares of KemPharm Inc which is valued at $6.3 Million.KemPharm Inc makes up approximately 3.93% of Arete Wealth Advisors’s portfolio.
Other Hedge Funds, Including , Kennedy Capital Management boosted its stake in KMPH in the latest quarter, The investment management firm added 5,211 additional shares and now holds a total of 55,126 shares of KemPharm Inc which is valued at $331,859. KemPharm Inc makes up approx 0.01% of Kennedy Capital Management’s portfolio. Sg Americas Securities added KMPH to its portfolio by purchasing 9,647 company shares during the most recent quarter which is valued at $58,075. Manufacturers Life Insurance Company The added KMPH to its portfolio by purchasing 453 company shares during the most recent quarter which is valued at $2,727.Blackrock Institutional Trust Company N.a. boosted its stake in KMPH in the latest quarter, The investment management firm added 1,653 additional shares and now holds a total of 35,485 shares of KemPharm Inc which is valued at $213,620.
KemPharm Inc closed down -0.02 points or -0.33% at $6.03 with 1,46,601 shares getting traded on Wednesday. Post opening the session at $6.06, the shares hit an intraday low of $5.95 and an intraday high of $6.06 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
Many Wall Street Analysts have commented on KemPharm Inc. Shares were Reiterated by RBC Capital Mkts on May 6, 2016 to “Outperform” and Lowered the Price Target to $ 14 from a previous price target of $22 .
KemPharm Inc. is a United States-based clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of new molecular entity (NME) prodrugs. The Company through its Ligand Activated Therapy (LAT) platform technology creates NME prodrug product candidates. The Company’s NME prodrug product candidates include KP201/APAP KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder (ADHD) and KP303 for the treatment of central nervous system (CNS) disorders. The Company’s product’s KP201/APAP is in clinical trial stage and KP511/ER KP415 KP606/ER and KP303 are in preclinical trail stage.